Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
- Written by PR Newswire
Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease
MELBOURNE, Australia and SAN FRANCISCO, Aug. 25, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...
Read more: Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with...